Pfizer-BioNTech COVID-19 vaccine 95% effective in final trial

BioNTech/Pfizer to seek emergency approval for coronavirus vaccine within days

Drugmaker Pfizer has provided updated analysis around its COVID-19 vaccine Phase 3 clinical trial data, saying that in the final result of its analysis of the 44,000-participant trial, its COVID-19 vaccine candidate proved 95% percent effective.

The vaccine's efficacy was found to be consistent across different ages and ethnicities - a promising sign given the disease has disproportionately hurt the elderly and certain groups including Black people.

The companies said they'll also submit an application for emergency authorization with the U.S. Food and Drug Administration (FDA) and other worldwide regulators in the same time frame. Conditional approval in the European Union could come in the second half of December, Sahin added.

"If all goes well I could imagine that we gain approval in the second half of December and start deliveries before Christmas, but really only if all goes positively", he said.

Ontario expects to receive a combined 2.4 million doses of the Pfizer and Moderna COVID-19 vaccines during the first three months of 2021 with more to follow after that, Health Minister Christine Elliott says.

In the latest analysis, the companies looked into the confirmed COVID-19 cases of 170 study participants, eight of whom had been vaccinated while 162 had received dummy shots.

Pfizer said it has developed specially designed shipping containers that use dry ice to keep the temperature around -70 C. The containers can also be used as storage for 15 days, if the dry ice is refreshed. This is a big deal because other vaccines have been known to be less effective among older people, who are most at risk from getting seriously ill from Covid-19.


Due to the fact that recipients of both vaccines will require two doses 21 days apart, it is likely that the initial shipments will only be enough to protect about 1.2 million Ontarians. Pfizer shares were up 1.6 percent while BioNTech jumped 3.8 percent in the United States.

Scientists have welcomed the news that older people will achieve a good level of protection, with those over 65 years deemed to be at higher risk of severe illness from Covid-19 or death.

The announcement comes just days after similarly encouraging news from Moderna Inc. about its vaccine.

Mike Ryan, the World Health Organization's top emergency expert, said it would be at least 4-6 months before significant levels of vaccination were taking place around the world.

Andrew Hill is a researcher at the University of Liverpool's department of pharmacology.

If the vaccine is authorized, attention will immediately shift to how it will be distributed.

Related:

Comments

Latest news

NFL’s Pro Bowl Will Be ‘Played’ in Madden
Operating in the midst of a global pandemic has resulted in reduced fan attendance, canceled games, and players forced to sit out. The Pro Bowl game itself, scheduled for January 31 in Las Vegas, was called off last month because of the COVID-19 pandemic.

Coronavirus outbreak causes cancellation of Fiji v France Autumn Nations Cup game
Fiji's Autumn Nations Cup rugby match against Italy has been cancelled with the touring side ravaged by Covid-19. The decision follows after their 29 positive cases in the Fiji squad following the latest round of testing.

YouTube launches audio ads to target podcast, music audience
The giant video platform confirmed that the new Terms of Service will be effective in all regions by 2021. These lineups can be focused on a genre, such as Latin music or K-pop, or on an interest like fitness.

Pfizer's COVID vaccine could be approved by Health Canada in January
Pfizer said it has developed specially designed shipping containers that use dry ice to keep the temperature around -70 C. The ongoing late-stage trial is taking place at 150 sites in the US, Germany, Turkey, South Africa, Brazil and Argentina.

U.S. to label Israel boycott movement as ‘anti-Semitic’: Pompeo
Netanyahu congratulated Biden and referred to him as the president-elect in an official statement earlier this week. Amnesty does not take a position on the boycott movement.

Other news